Cryobiopsy at the dawn of fibrosis: unlocking early diagnosis and therapeutic windows.

Transbronchial lung cryobiopsy (TBLC) has rapidly established itself as a promising, less invasive alternative to surgical lung biopsy for the evaluation of interstitial lung diseases (ILDs). While its diagnostic accuracy and safety are increasingly recognized in clinically overt forms, its role within the more subtle spectrum of interstitial lung abnormalities (ILAs) and early ILDs remains insufficiently defined and therefore largely debated. In this expert narrative review, we explore the current state of evidence surrounding TBLC and its potential applicability in these emerging clinical entities, addressing technical variability, diagnostic performance, safety profile, and integration within multidisciplinary frameworks. We further examine the ethical and clinical tension arising from the use of invasive diagnostics to largely asymptomatic or minimally symptomatic individuals, where the balance between potential benefit and harm remains undefined. Beyond these pragmatic considerations, TBLC offers a unique vantage point into the onset of fibrotic remodeling: its broader application may unveil the earliest histopathologic and biological substrates of chronic and acute tissue injury in ILDs, including aberrant basaloid cells, potential indicators of maladaptive repair that may orchestrate the fibrotic cascade. By enabling recognition of usual interstitial pneumonia (UIP) at its inception, TBLC holds the promise not merely of refining risk stratification, but of opening new therapeutic horizons in which antifibrotic strategies may be deployed at a stage when disease is still modifiable. We contend that rigorously designed prospective studies are urgently needed to determine whether early tissue sampling with TBLC can transform ILAs from incidental findings into a window of therapeutic opportunity, thereby altering the otherwise progressive trajectory of fibrosing lung diseases.